bluebird bio (BLUE) Stock Forecast, Price & News

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for bluebird bio in the last twelve months. There are currently 1 sell rating, 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" BLUE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BLUE, but not buy additional shares or sell existing shares.
View BLUE analyst ratings or view top-rated stocks.

10 Wall Street research analysts have issued 12 month target prices for bluebird bio's shares. Their BLUE share price forecasts range from $3.00 to $10.00. On average, they anticipate the company's stock price to reach $7.25 in the next twelve months. This suggests a possible upside of 139.1% from the stock's current price.
View analysts price targets for BLUE or view top-rated stocks among Wall Street analysts.

bluebird bio's stock was trading at $6.92 at the beginning of 2023. Since then, BLUE shares have decreased by 56.2% and is now trading at $3.03.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our BLUE earnings forecast.

bluebird bio, Inc. (NASDAQ:BLUE) issued its earnings results on Tuesday, August, 8th. The biotechnology company reported ($0.67) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.72) by $0.05. The biotechnology company had revenue of $6.90 million for the quarter, compared to the consensus estimate of $11.30 million. bluebird bio had a negative trailing twelve-month return on equity of 37.89% and a negative net margin of 1,020.37%. The company's revenue was up 360.0% compared to the same quarter last year. During the same period last year, the business earned ($1.29) EPS.

ETFs with the largest weight of bluebird bio (NASDAQ:BLUE) stock in their portfolio include Direxion Moonshot Innovators ETF (MOON), Virtus LifeSci Biotech Products ETF (BBP), Horizon Kinetics Medical ETF (MEDX), Global X Genomics & Biotechnology ETF (GNOM),

91 employees have rated bluebird bio Chief Executive Officer Nick Leschly on Glassdoor.com. Nick Leschly has an approval rating of 74% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other bluebird bio investors own include OPKO Health (OPK), BioMarin Pharmaceutical (BMRN), Puma Biotechnology (PBYI), NVIDIA (NVDA), Gilead Sciences (GILD), Incyte (INCY), Micron Technology (MU), Alibaba Group (BABA) and (MDVN) (MDVN).

bluebird bio trades on the NASDAQ under the ticker symbol "BLUE."

bluebird bio's stock is owned by many different institutional and retail investors. Top institutional investors include State Street Corp (15.30%), BlackRock Inc. (8.22%), Granahan Investment Management LLC (4.54%), Geode Capital Management LLC (2.08%), Credit Suisse AG (1.73%) and Dimensional Fund Advisors LP (1.30%). Insiders that own company stock include Alison Cecily Finger, Andrew Obenshain, Anne-Virginie Eggimann, David Davidson, Jason Cole, Jessica Whitten, Joanne Smith-Farrell, Katy Burnett, Nick Leschly, Richard A Colvin, Thomas J Klima and William D Baird III.
View institutional ownership trends.

Shares of BLUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BLUE stock can currently be purchased for approximately $3.03.

bluebird bio (NASDAQ:BLUE) has a market capitalization of $324.06 million and generates $3.60 million in revenue each year. The biotechnology company earns $-266,580,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis.

The company employs 323 workers across the globe.

bluebird bio's mailing address is 60 BINNEY STREET, CAMBRIDGE MA, 02142. The official website for the company is www.bluebirdbio.com. The biotechnology company can be reached via phone at (339) 499-9300 or via email at investor@bluebirdbio.com.